KALA BIO to Present at H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Rhea-AI Summary

KALA BIO (NASDAQ:KALA), a clinical-stage biopharmaceutical company focused on innovative therapies for rare and severe eye diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer, will deliver a pre-recorded presentation available from August 15, 2024, at 7:00 a.m. ET.

The company's management team will also be available for virtual one-on-one meetings throughout the conference. Interested parties can access the webcast and subsequent recording of the presentation through the 'Presentations' section of KALA BIO's website at www.kalarx.com.

ARLINGTON, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will present at the H.C. Wainwright 4th Annual Ophthalmology Conference, which is being held virtually. A pre-recorded presentation will be made available beginning on Thursday, August 15, 2024 at 7:00 a.m. ET. Management will also be available for virtual one-on-one meetings throughout the conference.

To access the webcast and subsequent archived recording of the presentation, please visit the “Presentations” section of the KALA website at www.kalarx.com.

About KALA BIO, Inc.

KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA, please visit www.kalarx.com.

Investor Contact:

Taylor Steiner
taylor.steiner@precisionaq.com
212-362-1200

FAQ

When is KALA BIO presenting at the H.C. Wainwright Ophthalmology Conference?

KALA BIO's pre-recorded presentation will be available starting August 15, 2024, at 7:00 a.m. ET at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference.

Who will be presenting for KALA BIO at the conference?

Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer of KALA BIO, will be presenting at the conference.

How can investors access KALA BIO's presentation at the conference?

Investors can access the webcast and recording of the presentation through the 'Presentations' section of KALA BIO's website at www.kalarx.com.

What is KALA BIO's focus as a biopharmaceutical company?

KALA BIO is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing innovative therapies for rare and severe diseases of the eye.

Will KALA BIO's management be available for meetings during the conference?

Yes, KALA BIO's management will be available for virtual one-on-one meetings throughout the H.C. Wainwright Ophthalmology Conference.